{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:20:01Z","timestamp":1780377601097,"version":"3.54.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To determine the relationship between the number of plasma exchanges and clinical outcome in patients experiencing myasthenic crisis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We retrospectively reviewed all episodes of myasthenia gravis exacerbation\/crisis who received plasmapheresis in patients admitted to a single-center tertiary care referral center from July 2008 to July 2017. We performed statistical analyses to determine whether the increased number of plasma exchanges improves the primary outcome (hospital length of stay) and the secondary outcome (disposition to home, skilled nursing facility, long-term acute care hospital, or death).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There is neither clinically observable nor statistically significant improvement in length of stay or disposition on discharge in patients who received 6 or greater sessions of plasmapheresis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study provides class IV evidence that extending the number of plasma exchanges beyond 5 does not correlate with decreased hospital length of stay or improved discharge disposition in patients experiencing myasthenic crisis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cnd.0000000000000421","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:03:22Z","timestamp":1684854202000},"page":"199-206","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Greater Number of Plasma Exchanges Does Not Improve Outcome in Myasthenic Crisis"],"prefix":"10.1097","volume":"24","author":[{"given":"Michael","family":"Hansen","sequence":"first","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1866-0344","authenticated-orcid":false,"given":"Lee","family":"Neilson","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Parikh","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Katirji","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250507","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol"},{"key":"R2-20250507","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"R3-20250507","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","article-title":"Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas","year":"1997","journal-title":"Neurology"},{"key":"R4-20250507","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1468-1331.2009.02634.x","article-title":"Long-term effects of combined immunosuppressive treatment on myasthenic crisis","volume":"16","author":"R\u00f3zsa","year":"2009","journal-title":"Eur J Neurol"},{"key":"R5-20250507","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1749-6632.1981.tb33765.x","article-title":"Aspects of the natural history of myasthenia gravis: crisis and death","volume":"377","author":"Cohen","year":"1981","journal-title":"Ann NY Acad Sci"},{"key":"R6-20250507","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"key":"R7-20250507","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1385\/NCC:3:3:189","article-title":"Myasthenic crisis","volume":"3","author":"Lacomis","year":"2005","journal-title":"Neurocrit Care"},{"key":"R8-20250507","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SMJ.0b013e31815d4398","article-title":"Myasthenia gravis crisis","volume":"101","author":"Bershad","year":"2008","journal-title":"South Med J"},{"key":"R9-20250507","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"key":"R10-20250507","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"R11-20250507","first-page":"478","article-title":"Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital","volume":"92","author":"Pittayanon","year":"2009","journal-title":"J Med Assoc Thai"},{"key":"R12-20250507","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"key":"R13-20250507","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"R14-20250507","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/0300060516669893","article-title":"Predictors of extubation outcomes following myasthenic crisis","volume":"44","author":"Liu","year":"2016","journal-title":"J Int Med Res"},{"key":"R15-20250507","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","year":"1997","journal-title":"Lancet."},{"key":"R16-20250507","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"R17-20250507","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1744-9987.2009.00684.x","article-title":"Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up","volume":"13","author":"Triantafyllou","year":"2009","journal-title":"Ther Apher Dial"},{"key":"R18-20250507","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12288-016-0661-3","article-title":"Therapeutic plasma exchange in patients with neurologic disorders: review of 63 cases","volume":"33","author":"Tombak","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R19-20250507","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jamainternmed.2017.3628","article-title":"Don't just do something, stand there","volume":"177","author":"Sinha","year":"2017","journal-title":"JAMA Intern Med"},{"key":"R20-20250507","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","article-title":"Advances in autoimmune myasthenia gravis management","volume":"18","author":"Wang","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"R21-20250507","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/NRL.0000000000000026","article-title":"IVIG versus PLEX in the treatment of worsening myasthenia gravis: what is the evidence?: a critically appraised topic","volume":"19","author":"Dhawan","year":"2015","journal-title":"Neurologist"},{"key":"R22-20250507","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1526-0968.2000.004004291.x","article-title":"The six year experience of plasmapheresis in patients with myasthenia gravis","volume":"4","author":"Chiu","year":"2000","journal-title":"Ther Apher"},{"key":"R23-20250507","doi-asserted-by":"crossref","first-page":"e19100","DOI":"10.1097\/MD.0000000000019100","article-title":"Lower number of plasma exchange sessions and glomerular filtration rate decline are associated with second relapses in patients with myasthenia gravis","volume":"99","author":"Premuzic","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R24-20250507","first-page":"346","article-title":"The efficacy of plasma exchange in the removal of plasma components","volume":"104","author":"Derksen","year":"1984","journal-title":"J Lab Clin Med"},{"key":"R25-20250507","first-page":"60","article-title":"Plasmapheresis in clinical medicine","volume":"138","author":"Linker","year":"1983","journal-title":"Med Prog"},{"key":"R26-20250507","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"Br J Haematol"},{"key":"R27-20250507","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000014434","article-title":"Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange","volume":"18","author":"Tesa\u0159","year":"2000","journal-title":"Blood Purif"},{"key":"R28-20250507","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1468-1331.2009.02729.x","article-title":"Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis","volume":"16","author":"Yeh","year":"2009","journal-title":"Eur J Neurol"},{"key":"R29-20250507","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1309\/L0DG8YU2WE5DV58H","article-title":"Changes in the lymphocyte subset after double-filtration plasmapheresis","volume":"128","author":"Yeh","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"R30-20250507","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"}],"container-title":["Journal of Clinical Neuromuscular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T21:02:54Z","timestamp":1746651774000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CND.0000000000000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cnd.0000000000000421","relation":{},"ISSN":["1522-0443"],"issn-type":[{"value":"1522-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}